Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers

PURPOSE: Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. M...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Jackson, Tiffiny L., Fu, Siqing, Naing, Aung, Tsimberidou, Apostalia M., Moulder, Stacy L., Hong, David S., Yang, Hui, Piha-Paul, Sarina A., Atkins, Johnique T., Garcia-Manero, Guillermo, Kurzrock, Razelle
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148903/
https://ncbi.nlm.nih.gov/pubmed/24435060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2384-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky